PIK3CB and head and neck squamous cell carcinoma: It still remains to be examined if mutations of other major players of the PI3K pathway (e.g., MTOR, TSC1/2) can also confer sensitivity to PI3K/mTOR inhibitors in HPV(+) HNSCC or not.